Contact this trialFirst, we need to learn more about you.
Prophylaxis
Oral PHA-022121 for Hereditary Angioedema
Recruiting0 awardsPhase 2
Ann Arbor, Michigan
This trial is testing a new drug to see if it can prevent hereditary angioedema attacks. The study will have 30 patients and will last for 12 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service